MetaCap

Galectin Therapeutics (GALT) vs Vicore Pharma AB (VCRE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Galectin Therapeutics is the larger company by market cap ($271.4 million vs $264.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GALT-41.90%VCRE-42.12%
+18%-16%-50%
Jul 6, 20261 yearNov 20, 2026
GALT-33.74%VCRE-31.75%
+16%-11%-37%
Jul 6, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GALT versus VCRE key metrics
MetricGALTVCRE
Share price$2.69$9.41
Market cap$271.35M$264.89M
1-day change-4.27%-5.09%
YTD return-35.34%—
1-year return-49.72%—
5-year return+4.67%—
EPS (TTM)$-0.32$-2.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-30.84M—
52-week high$7.13$17.80
52-week low$2.03$7.88
Distance from 52-week high-62.27%-47.16%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+308.92%+158.90%
Average volume252.31K23.31K
Shares outstanding100.88M28.16M
Employees950
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Galectin Therapeutics

GALT stock →

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

About Vicore Pharma AB

VCRE stock →

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.

Health Care · Biotechnology: Pharmaceutical Preparations · 50 employees

GALT vs VCRE FAQ

Which is bigger, Galectin Therapeutics or Vicore Pharma AB?

Galectin Therapeutics (GALT) is larger, with a market capitalization of $271.35M compared with $264.89M for Vicore Pharma AB (VCRE).

Are Galectin Therapeutics and Vicore Pharma AB in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons